 Chlorambucil
"Chlorambucil" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
| Descriptor ID |
D002699
|
| MeSH Number(s) |
D02.455.526.728.650.156
|
| Concept/Terms |
Chlorambucil- Chlorambucil
- 4-(Bis(2-chloroethyl)amino)benzenebutanoic Acid
- N,N-Di-(2-chloroethyl)-p-aminophenylbutyric Acid
- Chloraminophene
- Chlorbutin
|
Below are MeSH descriptors whose meaning is more general than "Chlorambucil".
Below are MeSH descriptors whose meaning is more specific than "Chlorambucil".
This graph shows the total number of publications written about "Chlorambucil" by people in this website by year, and whether "Chlorambucil" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 | | 1999 | 0 | 1 | 1 | | 2019 | 0 | 1 | 1 | | 2020 | 1 | 0 | 1 | | 2021 | 0 | 1 | 1 | | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Chlorambucil" by people in Profiles.
-
Burger JA, Robak T, Demirkan F, Bairey O, Moreno C, Simpson D, Munir T, Stevens DA, Dai S, Cheung LWK, Kwei K, Lal I, Hsu E, Kipps TJ, Tedeschi A. Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. Leuk Lymphoma. 2022 06; 63(6):1375-1386.
-
Chien HC, Morreall D, Patil V, Rasmussen KM, Yong CM, Li CY, Passey DG, Burningham Z, Sauer BC, Halwani AS. Real-world treatment patterns and outcomes in a national study of veterans with Waldenstr?m macroglobulinemia, 2006-2019. Am J Hematol. 2021 06 01; 96(6):E184-E187.
-
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Salles G, Wierda WG, Izumi R, Munugalavadla V, Patel P, Wang MH, Wong S, Byrd JC. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020 04 18; 395(10232):1278-1291.
-
Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, Bairey O, Hillmen P, Coutre SE, Devereux S, Grosicki S, McCarthy H, Simpson D, Offner F, Moreno C, Dai S, Lal I, Dean JP, Kipps TJ. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020 03; 34(3):787-798.
-
Enzenauer RW, Brozetti JJ, Dragoo RA. Central retinal vein occlusion in a patient with IgG lambda monoclonal gammopathy. Arch Ophthalmol. 1999 Jan; 117(1):134-5.
-
Lampe JN, Kutyavin IV, Rhinehart R, Reed MW, Meyer RB, Gamper HB. Factors influencing the extent and selectivity of alkylation within triplexes by reactive G/A motif oligonucleotides. Nucleic Acids Res. 1997 Oct 15; 25(20):4123-31.
-
Moreland L, Alarc?n GS. Comment on the article by Furst et al. Arthritis Rheum. 1989 Dec; 32(12):1631-2.
-
Vandenberg SA, Kulig K, Spoerke DG, Hall AH, Bailie VJ, Rumack BH. Chlorambucil overdose: accidental ingestion of an antineoplastic drug. J Emerg Med. 1988 Nov-Dec; 6(6):495-8.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|